BioCentury on BioBusiness, Cover Story
Table: What Could Have Been
Back to the parent article
Published on Monday, July 12, 2010
Since the start of 2008, at least 19 companies in
Biogen Idec's main areas of interest - autoimmune, cancer, cardiovascular and
neurology - were acquired for $500 million or more. (A) Status of programs at
the time of the deal. Source: BCIQ: BioCentury Online Intelligence
|
Year
|
Target
|
Acquirer
|
Value
|
Major
assets (A)
|
|
2010
(prop)
|
Abraxis
BioScience Inc. (NASDAQ:ABII)
|
Celgene
Corp. (NASDAQ:CELG)
|
$2.9B
plus $650M milestones
|
Breast
cancer drug Abraxane nab-paclitaxel, with 2009 revenues of $314.5
|
|
2010
(prop)
|
TargeGen
Inc.
|
sanofi-aventis
Group (Euronext:SAN; NYSE:SNY)
|
$75M
plus $485M milestones
|
Small
molecule kinase inhibitors, including lead compound TG 101348, which has
completed a Phase I/II trial to treat myelofibrosis
|
|
2010
|
Corthera Inc.
|
Novartis AG (NYSE:NVS;
SIX:NOVN)
|
$120M plus $500M milestones
|
Relaxin recombinant human relaxin-H2 in Phase III
testing to treat acute decompensated heart failure
|
131 words displayed of 601 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]